AusperBio Closes $120M Series C for AHB-137 Hepatitis B Program
AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial...
AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial...
MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal study...
Genentech partners with DualityBio on next-generation ADC payloads designed to overcome topoisomerase inhibitor resistance in cancer patients.
SPY072 missed its primary endpoint in a rheumatoid arthritis study, narrowing the drug candidate's development path outside inflammatory bowel...
Generate Biomedicines' GB-0895 Phase 1 data released early, showing results in mild-to-moderate asthma and COPD ahead of ERS presentation.
Ivonescimab beats durvalumab in Phase III HARMONi-GI1 trial for biliary tract cancer, meeting primary overall survival endpoint as first-line...
AbbVie seeks EMA approval for SKYRIZI subcutaneous induction in Crohn's disease following Phase 3 AFFIRM trial success.
Tezspire hits both primary endpoints in Phase 3 eosinophilic esophagitis trial, addressing histologic remission and dysphagia symptom relief through...
Theravance files ampreloxitine investor presentation based on post hoc analyses of its Phase 3 CYPRESS trial in multiple system...
Caliway's Phase 3 SUPREME-01 trial for CBL-514 now enrolling patients. The pivotal study evaluates abdominal fat reduction using the...